World Health Organization

Sri Lanka

Sri Lanka

HIV Country Profile 2022

English

WHO/UCN/HHS/21.10


82%

 \checkmark

Demographic and socioeconomic data			
Total population (July 2021)	GNI per capita, PPP (Current international \$) (2021)		
21.773 million	\$ 13 790 US\$		
Maternal mortality per 100 000 live births (2017) 36	Health expenditure total (% of GDP) (2019) \$ 4%		
Espérance de vie (années) (2021)	Health expenditure per capita, US\$ (2019)		
54.8 years	\$ 161 US\$		
Taux de fécondité (enfant/femme) (2021)	Human development index value (2019)		
Q 2.0	0.782		

 \checkmark

Progress towards HIV testing and treatment cascade targets by 2025 (2021)



Targets for 2025:

- 95 percent of people living with HIV know their status

- 90 percent of people living with HIV are on antiretroviral therapy

- 86 percent of people living with HIV are virally suppressed

These targets are related to the 95-95-95 targets by 2025, in which 95% of people living with HIV know their status, 95% of people who know their HIV-positive status are on antiretroviral therapy, and 95% of people on antiretroviral therapy are virally suppressed.


Health sector	cascade (2021)	
Indicator	Value	Percent of 95-95-95

2 974


Estimated % of pregnant women living with HIV who received ARVs for PMTCT (2021)

People living with HIV who know their status

Estimated ART coverage children and adults (2021)



Estimated number of people newly infected with HIV




Trends since 2010 (-59%)

Epidemiological HIV data (2021)	Value
Estimated number of women (15+) living with HIV	1 100
Estimated number of people living with HIV	3 600
Estimated incidence rate per 1000 uninfected population	< 0.01
Estimated number of people dying from HIV-related causes	< 100
Estimated number of people newly infected with HIV	< 200
Estimated number of children aged 0 to 14 living with HIV	N/A

Reported number of people living with HIV receiving ART	2 402	66%
People living with HIV with viral load suppression	2 010	55%

Estimated number of deaths due to AIDS



Trends since 2010 (-57%)

Prevention of mother-to-child transmission (PMTCT)	Value	Year
Antenatal care attendees who were tested for syphilis (%)	99.7%	2019
Antenatal care coverage - at least one visit (%)	98.8%	2016
Antenatal care attendees who tested positive for syphilis and who received benzathine penicillin IM (%)	97.7%	2019
% of pregnant women with known HIV status	92.9%	2021
Antenatal care coverage - at least four visits (%)	92.5%	2007
% of infants born to women living with HIV receiving a virological test within two months of birth (EID) ¹ (%)	16%	2010
Reported number of pregnant women living with HIV who received	16	2021

Antiretroviral therapy (ART) (2021)		
Estimated ART coverage	66%	
Estimated ART coverage (adults 15+)	66%	
Estimated ART coverage (children, 0-14) ¹	N/A	
Reported number of children receiving ART	39	
Reported number of people living with HIV receiving ART	2 402	
Reported number of people living with HIV receiving ART (adults 15+)	2 363	

Reported number of pregnant women living with HIV who received antiretrovirals for PMTCT

Tracing indicators for elimination of mother-to-child transmission. A color scheme (green, orange, red) is used to indicate if the country is on target to meet 2020 targets: 190% 295% 3Less than 5

Key populations (2021) HIV prevalence among men who have sex with men (%) 0.2% HIV prevalence among people who inject drugs (%) N/A HIV prevalence among sex workers (%) 0.3% Needles distributed per person who inject drugs per year N/A Percentage condom use among sex workers with most recent client 83.6% Percentage of people who inject drugs receiving OST N/A



First line Second line ◆ [TDF+FTC+EFV] [600+200+300]mg ◆ [ZDV+3TC+NVP] [150+200+300]mg $(TDF+3TC]+[LPV/r] \quad (TDF+FTC]+[LPV/r] \quad (ZDV+3TC]+[LPV/r]$ ollars per person per year 200 уеа per 600 150 per ollars 400 100 US d in US

	Median pri-
0 2010 2011 2012 2013 2014	4 0 2010 2011 2012 2013 2014
Year	Year
National HIV	policies and plans (2022)
Indicator	Value
Dolutegravir (DTG) as part of 1st line ARVs for adults and adolescents	DTG introduced in national guidelines and procurement initiated
Frequency of ART pick-up (MMD)	Every 3 months for adults who are doing well on ART
Frequency of clinic visits	Every 3 months for adults who are doing well on ART
Adoption of policy on advanced HIV	Fully adopted
mplementation of lifelong ART to pregnant & breastfeeding women	Implemented
mplementation of national policy on viral load monitoring	Implemented countrywide (>95% of treatment sites)
mplementation of treat all adults and adolescents	Implemented countrywide (>95% of treatment sites)
Implementation of national policy on HIV self-testing (HIVST)	No HIVST policy but policy in development
Rapid ART initiation	Other
Point-of-care viral load testing available	Point-of-care viral load testing available in any health facility
National policy supporting community delivery of ART	Policy implemented
National M&E plan or strategy for HIV	Stand-alone HIV monitoring and evaluation strategy or plan

Treatment initiation threshold adults and adolescents

Treatment initiation threshold children

Treat all, regardless of age

Treat All regardless of CD4 count

Sources: Global AIDS Monitoring (UNAIDS/WHO/UNICEF), Spectrum estimates (UNAIDS/WHO), WHO HIV Country Intelligence Tool, Global Health Observatory (WHO), Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat, World Bank, Global Health Expenditure Database (WHO), United Nations Development Programme, UNICEF data, Global Price Reporting Mechanism (WHO)

Definition of acronyms : PLHIV = People living with HIV, HIV = Human Immunodeficiency Virus, AIDS = Acquired Immunodeficiency Syndrome, ART = Antiretroviral Therapy, ARVs = Antiretrovirals, PMTCT = Prevention of Mother-to-Child Transmission, EID = Early Infant Diagnosis, OST = Opioid Substitution Therapy

© WHO 2022. Some rights reserved. Licence CC BY-NC-SA 3.0 IGO